UCLP Trials

New clinical trial for patients presenting with neuromyelitis optica (NMO) or NMO-spectrum disorder (NMOSD). This study is being run on the Royal London Hospital site.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Eligibility
Ages Eligible for Study: 18 Years to 74 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:
1. NMO or NMOSD
2. Age 18 to 74 years, inclusive at the time of informed consent.

Exclusion Criteria:
1. Pregnancy or lactation.
2. Evidence of other demyelinating disease or PML.
3. Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.

The following is a crib sheet to be used for screening.



Last Updated: 17th Sept 2014

The following is a graphic of MS@UCLP's clinical trial programme. 




Please note you cannot self-refer for clinical trials; you have to be referred to active UCLP sites via your neurologist or general practioner. The following neurologists are the clinical leads for MS trials at the four regional neuroscience centers that are part of UCLP:


1. Royal London Hospital, Barts Health, Dr Ben Turner

2. Royal Free Hospital, Dr Robert Brenner
3. Queen's Hospital, Romford, Dr Abhijit Chaudhuri
4. National Hospital for Neurology and Neurosurgery, UCLH, Dr Jeremy Chataway

Alemtuzumab

  1. An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
  2. Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
  3. Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Cladribine
  1. Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Daclizumab
  1. Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Subjects With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.
  2. Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis
  3. Long-Term Extension Study in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of DAC HYP
Dronabinol
  1. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
Fingolimod
  1. FTY720 in Patients With Primary Progressive Multiple Sclerosis
Laquinimod
  1. A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
  2. Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
  3. The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
  4. A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Medi-551
  1. Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Natalizumab
  1. A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
  2. Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
  3. Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
  4. Natalizumab Re-Initiation of Dosing
Ocrelizumab
  1. A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
  2. A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Phenytoin
  1. Neuroprotection With Phenytoin in Optic Neuritis
Raltegravir
  1. Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
Simvastatin
  1. Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
Siponimod
  1. Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Teriflunomide
  1. Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
  2. Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
  3. Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
Disclaimer: This site if for trial information only; for more details click on the trial link and/or ask your neurologist or MS clinical nurse specialist.

5 comments:

  1. is it possible to talk to some body of importance about a theory I have buy phone its in reference to blood flow , stress, heat and what could be the starting of ms.

    ReplyDelete
  2. Are there any stem cell trials being planned for 2015, which are going to be recruiting ?

    ReplyDelete
  3. When you say location, what does that mean? what if one could travel to London to be part of this trial?

    ReplyDelete
  4. Are there any trials that are currently recruiting for secondary MS?

    ReplyDelete
    Replies
    1. Yes but this list needs updating they need up dating there is MS-STAT2

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.